This is your chance to invest in next-generation therapeutics for cancer and autoimmune disease that build on the groundbreaking work of two Lasker Award-winning scientists.
Play Video


Anyone can invest


$25,000 minimum

Company Highlights

Enosi (from Greek ‘enosis’ meaning combination) was formed by Professor Sir Marc Feldmann and Dr. H. Michael Shepard to combine technologies from cancer and autoimmune disease research to create novel and more effective drugs for each disease.

  • Dr. Feldmann:  Best known for inventing TNF Blockers (~$40B/year industry)
  • Dr. Shepard: Best known for the trastuzumab/Herceptin franchise of Genentech/Roche (~$10B/year).
  • Both are recipients of the Albert and Mary Lasker Award for Clinical Research

These industry-leading experts will combine their talents, networks and experience to address the growing global health challenges of autoimmune diseases, cancer and acute inflammatory conditions.

Lasker Foundation
Enosi Life Sciences 506(c) Offering
Enosi Life Sciences Corp.
$8.00 per share
Open to accredited investors in accordance with Reg. D 506(c)

View Enosi Life Sciences’ official Form D as filed with the United States Securities and Exchange Commission (SEC)

Research TargetS

All TNF blockers and JAK inhibitors have black box warnings related to opportunistic infections, cancer and now cardiovascular events. New drugs with a different mechanism of action are needed to address these problems.

The company is focusing its attention on two projects that are new to treatment of rheumatoid arthritis and other autoimmune disease.

The first project is a specific inhibitor of TNFR1 (EN1001) and the second is a growth factor trap that inactivates inflammatory growth factors which otherwise would induce proliferation of cells that produce TNF in the synovial joints of rheumatoid arthritis patients (EN2001).

Both are new chemical entities that work by novel mechanisms of action and are covered by Enosi’s patent filings. Both programs have precursor molecules with existing in vitro and in vivo proof of concept in animal models of rheumatoid arthritis (RA). EN2001 precursor molecule also has activity in vitro and in vivo in cancer models.

Two other programs are anticipated when funding allows. The first is an anti-TNFR2 program (two products), and the second is an innovative multi-specific antibody-like drug and targeting platform.

Corporate Presentation

Learn about Enosi Life Sciences’ mission, founders, and exciting new scientific research targets for next-generation treatments of cancer and autoimmune diseases.

About Enosi Life Sciences

January 2020 (Delaware)
San Diego, CA

Market Opportunity

Total Addressable Market: $346.6+ billion by 2026
Cancer and autoimmune therapy markets are huge—and growing

The global cancer immunotherapy market is expected to grow at a CAGR of around 10.6% from 2019 to 2026 and expected to reach the market value of around US$ 115.4 Bn by 2026

Monoclonal antibody market
  • $125b in 2020
  • Projected to reach over $148.9B by 2026 (Source)
  • $40b+ TNF Inhibitors
  • Projected to be $42.1b by 2026 (Source)
Potential Other MAb TNF Inhibitor Markets for Enosi Molecules
  • Organ Transplant/Rejection Inhibitors: $18.21b by 2023 (Source)
  • Alzheimer’s: $10.5b by 2025 (Source)
  • Parkinson’s: $8.3b by 2026 (Source)
  • Acute Respiratory Distress Syndrome (ARDS): $990.88m by 2027
  • Cachexia (as related to cancer and geriatric population): $2.2b by 2024

Competitive AdvantageS

Acknowledged research/content experts
  • Feldmann and Shepard have both drug discovery and drug development successes.
  • Feldmann discovered TNF Blockers for autoimmune disease (~40B/y).
  • Shepard discovered trastuzumab (Herceptin)
  • Trastuzumab and its franchise are worth about $10B/y
  • Shepard headed up discovery programs at Canji/Schering Plough (gene therapy), NewBiotics (small molecule prodrugs), Receptor Biologics (dominant negative soluble receptors), and Halozyme (drug delivery and cancer therapeutics).
Experience & Networks
  • Proven experience in developing, marketing, and commercializing drugs
  • Demonstrated proficiency
  • Reduced costs by outsourcing non-IP-related operations
  • Substantial biotech/pharma, institutional investor, regulatory, academic, etc., network
  • Cost-effective and efficient preclinical and clinical development by leveraging academic resources
Two Patents Filed
  • PCT International Application Number PCT/US2020/018739: Filed February 19, 2020
  • Provisional Patent: Filed August 28, 2020
  • These cover Enosi’s technology, compositions of matter, and methods of use.

Timelines to Phase I/II CLINICAL TRIALS


Enosi Life Sciences founded

Dr. H. Michael Shepard and Professor Sir Marc Feldmann join forces

3-4 years

EN1001 – Anti-TNFR1

4 years

EN2001 – Growth Factor Trap for RA